At our last reported quarter we had 53.4 million about a 100 million shares outstanding. We did not have any debt , it trades very well we do own this entirely. So we do have partnership opportunities it's something that we are exploring right now. And I think that the cash structure is uncomplicated.
We don't have any variable rate financing vehicles. We don't have an ATM, e-lock or anything like that it's a pretty straight forward story, if anything it's encumbered by the fact that it's relatively new. We spend a year and a half or up to two years, preparing for this sickle cell trial and it's a new space.
"So the challenge for us as drug developers is not to show that 188 can improve blood flow. We know that it improves blood flow. We have to show that an improvement in blood flow leads to reached to a clinically relevant outcome. There has been a lot of studies done to date, these mix up of slides were studies done by a prior sponsor of this drug, but there have been a number of studies that have been done to date have been to that MST-188 is having a clinically relevant effect. "